ACCESS Newswire

CBD Life Sciences Inc.

21.7.2021 13:01:50 CEST | ACCESS Newswire | Press release

Share
CBD Life Sciences, Inc. (CBDL) Debuts Delta-10 Cartridges

SCOTTSDALE, AZ / ACCESSWIRE / July 21, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with all-new Delta-10 Cartridges.

CBD Life Sciences Inc. is finally ready to debut two different strains of Delta-10 Cartridges. The two strains are Sour Diesel & Blue Dream, and both are 900MG for each one. Delta 10-THC or Delta 10-Tetrahydrocannabinol is a brand new, cutting edge cannabinoid (derived from Hemp) which carries similar psychoactive effects and euphoric feelings associated with the traditional cannabis use. Additionally, these cannabinoids are known for their anti-nausea, anti-anxiety, appetite stimulating and stress reducing properties. President & CEO Lisa Nelson stated "Delta-10 definitely has the power to change the CBD market dramatically!" This is going to be a top selling product for CBD Life Sciences Inc. online distribution in the upcoming weeks along with the Pain Relief Roll-On that launched on Amazon last week.

CBD Life Sciences Inc. surpasses the competition with the little amounts of extra ingredients we use. Sourcing only the best Delta 10 Distillate we then take the cleanest terpenes and infuse them to bring you these products that will not disappoint! Our new Delta 10 products are lab tested for quality both in the raw form and in the finished product. Delta 10-THC is superior to the traditional and illegal Delta 9-THC because it carries basically every benefit and effect of Delta 9-THC but is fully federally legal and legal in 38 states in the United States. Most clients opt for Delta 8 as their sleeping aid. They prefer Delta 10 when it comes to promoting greater creativity, energy, alertness, and euphoria. Delta 10 is generally uplifting and ideal for daytime use. It also can appeal to a mass audience interested in psychoactive advantages without fear of meeting delta 9's outcomes. It is safe to say that Delta 10 will become more popular since it provides enhanced focus without the paranoia of Delta 9.

CBD Life Sciences Inc. is getting close to its 3rd retail location along with a recreational marijuana facility. This will be significant as far as expansion and revenue go and CBD Life Sciences Inc. will keep the public informed moving forward.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Link to Greenhouse Video: https://streamable.com/yb7pyd

Link to Greenhouse Video 2: https://streamable.com/5md9ym

The number of benefits CBD has is tremendous! These benefits include help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson's, osteoporosis, and ALS. CBD can also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn's, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

LBC BIOSCIENCE INC. ONLINE STORE

LBC BIOSCIENCE'S Online Emporium

LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings - all at very reasonable prices. Check out LBC Bioscience Inc's newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.

Become a Distributor

  • Large Selection of Products (over 50 items and growing)
  • 100% USA Made Products 'organic & kosher.'
  • All Products are THC-FREE (they contain 0.00% THC)
  • Weekly Deals (new deals every week)
  • 20% off on all products using code 'LBC20.'

LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc's Main Website at www.lbcbioscienceinc.com
Twitter: https://www.twitter.com/lbcbioscience
Facebook: https://www.facebook.com/lbcbioscience
Instagram: https://www.instagram.com/lbcbioscience

Amazon: https://www.amazon.com/shops/lbcbioscienceinc

About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC's products can be viewed and purchased on the Company's website at www.lbcbioscienceinc.com.

Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: tenassociates33@gmail.com
Website: www.tenassociatesllc.com

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking

SOURCE: CBD Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/656378/CBD-Life-Sciences-Inc-CBDL-Debuts-Delta-10-Cartridges

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release

Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort

GTDC Highlights Distributors' Vital Role in Scaling AI Adoption and Digital Transformation15.4.2026 15:00:00 CEST | Press release

Industry leaders stress that digital platforms, support, and collaboration are essential to boost sales, engage channels, and respond to shifts in global trade, workforce shortages, and the rise of robotics and AI. Technology distribution is evolving as these "AI-first" partners emerge, developing and deploying original AI solutions that define a new era of applied AI. IT distributors help speed up cloud, AI, and emerging tech adoption by investing in advanced systems and services for vendors and solution providers. NOORDWIJK, NL / ACCESS Newswire / April 15, 2026 / IT distributors have become a driving force behind the sales and adoption of AI, advanced cloud and cybersecurity solutions and other next‑generation technologies based on research and discussions at this week's GTDC Summit EMEA conference. The quickly evolving digital landscape was a central theme of the annual channel executive event, hosted by the Global Technology Distribution Council (GTDC), the world's largest consort

Innodata to Report First Quarter 2026 Results15.4.2026 14:00:00 CEST | Press release

NEW YORK CITY, NY / ACCESS Newswire / April 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report First Quarter 2026 results after the market closes on Thursday, May 7, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 715 9871 North America, Toll Free (+44) 800 358 0970 United Kingdom (+1) 646 307 1963 International Participant Access Code 3150581 For Replay: (+1) 800 770 2030 North America-Toll Free (+1) 609 800 9909 International Playback ID 3150581 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available

Innodata to Report First Quarter 2026 Results15.4.2026 14:00:00 CEST | Press release

NEW YORK CITY, NY / ACCESS Newswire / April 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report First Quarter 2026 results after the market closes on Thursday, May 7, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 715 9871 North America, Toll Free (+44) 800 358 0970 United Kingdom (+1) 646 307 1963 International Participant Access Code 3150581 For Replay: (+1) 800 770 2030 North America-Toll Free (+1) 609 800 9909 International Playback ID 3150581 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available

Envision Pharma Group Strengthens Executive Leadership Team to Accelerate Growth, Innovation and Global Client Delivery15.4.2026 14:00:00 CEST | Press release

Two Senior Appointments Reinforce Commitment to Technology Integration and Scalable Pharmaceutical Services FAIRFIELD, CT / ACCESS Newswire / April 15, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed two senior executives to further strengthen its leadership team and focus on integrating innovative AI technologies across its portfolio to deliver more data-driven outcomes for clients. Jay Ferro has been appointed President, Technology and Chief Product Officer. He joins Envision from Clario, a global clinical trial endpoint and technology company, where he led platform modernization and operational transformation initiatives that helped position the company for its acquisition in October 2025. Ferro will oversee a combined technology and product organization responsible for shaping enterprise technology strategy, translating business needs into scalable product solutions, and ensuring investments align

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye